Katri Kaukinen

Dr. Katri Kaukinen


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2022 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PLPilvi Laurikka
Pilvi Laurikka
LKLaura Kivelä
Laura Kivelä
KKKalle Kurppa
Kalle Kurppa
KKKatri Kaukinen
Katri Kaukinen
Summary: Background: The best‐known symptoms of coeliac disease are related to the gastrointestinal tract, but the disease may also present with various systemic manifestations outside the intestine. Some of these consequences may remain permanent in undiagnosed individuals or if the diagnostic delay is prolonged. However, for many of the systemic manifestations, the scientific evidence remains scant and contradictory.Aims and Methods: We conducted a narrative review of the most thoroughly studied and clinically relevant systemic consequences of coeliac disease, especially those that could be prevented or alleviated by early diagnosis. The review is intended particularly for physicians encountering these patients in daily clinical practice.Results: The possible systemic consequences of coeliac disease extend to multiple organ systems, the best studied of which are related to skeletal, reproductive, cardiovascular and neurological systems. Furthermore, the disease is associated with an elevated risk of psychiatric comorbidities, non‐Hodgkin lymphomas and intestinal adenocarcinoma.Conclusions: The various systemic consequences of coeliac disease play a significant role in the overall health of patients. Early diagnosis and treatment with a gluten‐free diet appear to be beneficial for most, but not all of these conditions. The possible negative metabolic and psychosocial effects of the diet should be acknowledged during follow‐up.

1 October 1999 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
KKKatri Kaukinen
Katri Kaukinen
JSJ Salmi
J Salmi
JLJ Lahtela
J Lahtela
USU Siljamäki-Ojansuu
U Siljamäki-Ojansuu
AKAnna-Maija Koivisto
Anna-Maija Koivisto
PCP Collin
P Collin

8 September 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
VYVenla Ylönen
Venla Ylönen
KLKatri Lindfors
Katri Lindfors
MRMarleena Repo
Marleena Repo
HHHeini Huhtala
Heini Huhtala
VFValma Fuchs
Valma Fuchs
KKKalle Kurppa
Kalle Kurppa
Non-biopsy diagnosis of celiac disease is possible in children with anti-transglutaminase 2 antibodies (TGA) > 10× the upper limit of normal (ULN) and positive anti-endomysial antibodies (EMA). Similar criteria have been suggested for adults, but evidence with different TGA assays is scarce. We compared the performance of four TGA tests in the diagnosis of celiac disease in cohorts with diverse pre-test probabilities. Serum samples from 836 adults with either clinical suspicion or family risk of celiac disease were tested with four commercial TGA assays, EmA and celiac disease-associated genetics. The diagnosis was set based on duodenal lesion or, in some cases, using special methods. 137 (57%) patients with clinical suspicion and 85 (14%) of those with family risk had celiac disease. Positive predictive value (PPV) for 10×ULN was 100% in each TGA test. The first non-diagnostic investigations were encountered with ULN 1.0×–5.1× in the clinical cohort and 1.3×–4.9× in the family cohort, respectively. Using the assays’ own cut-offs (1×ULN) the PPVs ranged 84–100%. Serology-based diagnosis of celiac disease was accurate in adults using different commercial kits and pre-test probabilities using 10×ULN. The results also suggest that the ULN threshold for biopsy-omitting approach could be lower.

1 September 2015 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
KHKatriina Heikkila
Katriina Heikkila
OKO.A. Koskinen
O.A. Koskinen
AAArnav Agarwal
Arnav Agarwal
KTK.A.O. Tikkinen
K.A.O. Tikkinen
MMM. Mäki
M. Mäki
KKKatri Kaukinen
Katri Kaukinen

1 October 2019 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
EMEriika Mansikka
Eriika Mansikka
KHKaisa Hervonen
Kaisa Hervonen
KKKatri Kaukinen
Katri Kaukinen
TITuire Ilus
Tuire Ilus
POPia Oksanen
Pia Oksanen
TSTeea Salmi
Teea Salmi
Dermatitis herpetiformis (DH) is an extraintestinal manifestation of celiac disease causing an itchy, blistering rash. Granular IgA deposits in the skin are pathognomonic for DH, and the treatment of choice is a lifelong gluten-free diet (GFD). Preliminary evidence suggests that there are patients with DH who redevelop gluten tolerance after adherence to a GFD treatment. To evaluate this, we performed a 12-month gluten challenge with skin and small-bowel mucosal biopsy samples in 19 patients with DH who had adhered to a GFD for a mean of 23 years. Prechallenge biopsy was negative for skin IgA and transglutaminase 3 deposits in 16 patients (84%) and indicated normal villous height-to-crypt depth ratios in the small bowel mucosa in all 19 patients. The gluten challenge caused a relapse of the rash in 15 patients (79%) in a mean of 5.6 months; of these 15 patients, 13 had skin IgA and transglutaminase 3 deposits, and 12 had small-bowel villous atrophy. In addition, three patients without rash or immune deposits in the skin developed villous atrophy, whereas one patient persisted without any signs of relapse. In conclusion, 95% of the patients with DH were unable to tolerate gluten even after long-term adherence to a GFD. Therefore, lifelong GFD treatment remains justified in all patients with DH.

14 November 2014 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
ASAna-Marija Sulic
Ana-Marija Sulic
KKKalle Kurppa
Kalle Kurppa
TRTiina Rauhavirta
Tiina Rauhavirta
KKKatri Kaukinen
Katri Kaukinen
KLKatri Lindfors
Katri Lindfors
The only current treatment for celiac disease is a strict gluten-free diet. The ubiquitous presence of gluten in groceries, however, makes the diet burdensome and difficult to maintain, and alternative treatment options are thus needed. Here, the important role of transglutaminase 2 (TG2) in the pathogenesis of celiac disease makes it an attractive target for drug development. The present paper gives an overview of TG2 and addresses its significance in the pathogenesis of celiac disease. Moreover, the article summarizes preclinical studies performed with TG2 inhibitors and scrutinizes issues related to this therapeutic approach. Activation of TG2 in the intestinal mucosa is central in celiac disease pathogenesis and researchers have therefore suggested TG2 inhibitors as a potential therapeutic approach. However, a prerequisite for such a drug is that it should be specific for TG2 and not affect the activity of other members of the transglutaminase family. Such compounds have already been introduced and tested in vitro, but a major obstacle to further development is the lack of a well-defined animal model for celiac disease. Nonetheless, with encouraging results in preclinical studies clinical trials with TG2 inhibitors are eagerly awaited.